Non-Squamous Non-Small Cell Lung CancerPhase 2NCT01496742
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
A Phase 2 study testing RO5490258, bevacizumab [Avastin] and cisplatin/carboplatin in people with Non-Squamous Non-Small Cell Lung Cancer, run by Genentech, Inc. at 87 sites in 13 countries.
Trial summary
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV non-squamous non-small cell lung cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-Squamous Non-Small Cell Lung Cancer
- What is being tested?
- RO5490258, bevacizumab [Avastin] and cisplatin/carboplatin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 259 participants
- Where
- 87 sitesin 13 countries
- Study dates
- Apr 2012to Nov 2015
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients, >/= 18 years of age
- Histologically or cytologically confirmed Stage IIIB or Stage IV non-squamous non-small cell lung cancer (NSCLC)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- For patients who received prior adjuvant chemotherapy or chemoradiotherapy: a treatment-free interval of at least 12 months since last chemotherapy or chemoradiotherapy cycle
- Adequate tissue for central immunohistochemical (IHC) assay of Met receptor, and epidermal growth factor receptor (EGFR) testing if EGFR status is unknown
- Radiographic evidence of disease
Who cannot join
- Prior systemic treatment for Stage IIIB or IV non-squamous NSCLC
- Evidence of mixed NSCLC with a predominance of the squamous cell type
- Prior exposure to experimental treatment targeting either the hepatocyte growth factor (HGF) or Met pathway
- Patients with tumors confirmed to have EGFR-activating mutations who are suitable for anti-EGFR therapy (e.g. gefitinib or erlotinib), as determined by the investigator, unless that treatment is unavailable or refused by the patient
- Known central nervous system (CNS) disease, other than stable, treated brain metastases
- History of another malignancy in the previous 3 years, except for history of in situ cancer that was treated surgically with curative intent, localized prostate cancer that has been treated surgically with curative intent, or basal or squamous cell skin cancer
Show all 11Show fewer
- Uncontrolled diabetes
- Pregnant or lactating women
- Impaired bone marrow, liver or renal function (as defined by protocol)
- Significant history of cardiovascular disease
- Positive for HIV infection
Trial locations and contacts
87 sites in 13 countries.
87 sites in 13 countries
United States32 sites
Study site
Bakersfield, California, 93309
Study site
Bend, Oregon, 97701
Study site
Boynton Beach, Florida, 33435
Study site
Cleveland, Ohio, 44195
Study site
Columbus, Ohio, 43215
Study site
Fort Wayne, Indiana, 46815
Study site
Fort Wayne, Indiana, 46845
Study site
Fullerton, California, 92835
Study site
Grand Junction, Colorado, 81502-1628
Study site
Harvey, Illinois, 60426
Study site
Hickory, North Carolina, 28602
Study site
Hollywood, Florida, 33021
Study site
Huntsville, Alabama, 35805
Study site
Indianapolis, Indiana, 46260
Study site
Las Vegas, Nevada, 89148
Study site
Lawrenceville, Georgia, 30045
Study site
Los Angeles, California, 90024
Study site
Los Angeles, California, 90095-1772
Study site
Marietta, Georgia, 30060
Study site
Metairie, Louisiana, 70006
Study site
Middletown, Ohio, 45042
Study site
Minneapolis, Minnesota, 55454
Study site
Muncie, Indiana, 47303
Study site
New York, New York, 10016
Study site
Northridge, California, 91328
Study site
Orlando, Florida, 32804
Study site
Portland, Oregon, 97239
Study site
San Luis Obispo, California, 93454
Study site
Santa Barbara, California, 93105
Study site
Scottsdale, Arizona, 85259
Study site
Seattle, Washington, 98195
Study site
Stanford, California, 94305-5820
Italy6 sites
Study site
Avellino, Campania, 83100
Study site
Cremona, Lombardy, 26100
Study site
Milan, Lombardy, 20133
Study site
Orbassano, Piedmont, 10043
Study site
Rome, Lazio, 00149
Study site
Udine, Friuli Venezia Giulia, 33100
Germany5 sites
Study site
Göttingen, 37075
Study site
Halle, 06120
Study site
Immenhausen, 34376
Study site
München, 81925
Study site
Münster, 48149
Israel5 sites
Study site
Afula, 18101
Study site
Ashkelon, 78278
Study site
Holon, 58100
Study site
Tel Aviv, 6423906
Study site
Tsrifin, 6093000
Malaysia5 sites
Study site
George Town, 10050
Study site
Kuala Lumpur, 56000
Study site
Negeri Sembilan, 71800
Study site
Pulau Pinang, 11600
Study site
Tanjung Bungah, 11200
Philippines5 sites
Study site
Cebu City, 6000
Study site
Davao City, 8000
Study site
Pasig, 1605
Study site
Quezon City, 1104
Study site
Quezon City, 1114
Spain5 sites
Study site
Barcelona, Barcelona, 08036
Study site
Madrid, Madrid, 28007
Study site
Madrid, Madrid, 28050
Study site
Pamplona, Navarre, 31008
Study site
Zaragoza, Zaragoza, 50009
Taiwan5 sites
Study site
Kaohsiung City, 807
Study site
Taichung, 40705
Study site
Tainan, 704
Study site
Taipei, 00112
Study site
Taipei, 100
United Kingdom5 sites
Study site
Aberdeen, AB25 2ZN
Study site
Birmingham, B9 5SS
Study site
Bournemouth, BH7 7DW
Study site
Leeds, LS9 7TF
Study site
Manchester, M23 9QZ
France4 sites
Study site
Grenoble, 38043
Study site
Paris, 75230
Study site
Paris, 75674
Study site
Rennes, 35033
Latvia4 sites
Study site
Daugavpils, 5417
Study site
Liepāja, LV 3401
Study site
Riga, LV 1079
Study site
Riga, LV-1002
Argentina3 sites
Study site
Buenos Aires, C1426ANZ
Study site
La Rioja, F5300COE
Study site
Santa Rosa, L6304BOC
Mexico3 sites
Study site
Aguascalientes, 20234
Study site
Chihuahua City, 31000
Study site
León, 37150
About this study
Official title: A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV non-squamous non-small cell lung cancer. In Cohort 1, patients will be randomized to receive 4 cycles of bevacizumab (Avastin) 15 mg/kg iv, paclitaxel 200 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMab 15 mg/kg iv or placebo on Day 1 of each 21-day cycle. In Cohort 2, patients will be randomized to receive pemetrexed 500 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMAb 15 mg/m2 iv or placebo on Day 1 of each 21-day cycle. Patients who have not progressed after 4 cycles will be offered maintenance therapy with their assigned treatment of bevacizumab plus either MetMAb or placebo (Cohort 1) or pemetrexed plus either MetMAb or placebo (Cohort 2). Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Being tested
- Placebo, RO5490258, bevacizumab [Avastin], cisplatin/carboplatin, paclitaxel
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
RO5490258Drug
Also called MetMAb
15 mg/kg iv, Day 1 of each 21-day cycle
bevacizumab [Avastin]Drug
15 mg/kg iv, Day 1 of each 21-day cycle
cisplatin/carboplatinDrug
standard dose iv, Day 1 of each 21-day cycle, 4 cycles
paclitaxelDrug
200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
pemetrexedDrug
500 mg/m2, Day 1 of each 21-day cycle
| Study group | Role | What they receive |
|---|---|---|
| Bevacizumab+MetMAb | Experimental | Not described Receives: Drug: RO5490258; Drug: bevacizumab [Avastin]; Drug: cisplatin/carboplatin; Drug: paclitaxel |
| Bevacizumab+Placebo | Active comparator | Not described Receives: Drug: Placebo; Drug: bevacizumab [Avastin]; Drug: cisplatin/carboplatin; Drug: paclitaxel |
| Pemetrexed+MetMAb | Experimental | Not described Receives: Drug: RO5490258; Drug: cisplatin/carboplatin; Drug: pemetrexed |
| Pemetrexed+Placebo | Active comparator | Not described Receives: Drug: Placebo; Drug: cisplatin/carboplatin; Drug: pemetrexed |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-free survival (tumor assessments according to RECIST criteria)
Measured: up to approximately 23 months
Progression-free survival: Subgroup of patients with Met diagnostic positive tumors
Measured: up to approximately 23 months
Secondary outcomes (8)
Overall survival
Measured: up to approximately 23 months
Overall response rate (tumor assessments according to RECIST criteria)
Measured: up to approximately 23 months
Duration of response (time from first documented objective response to disease progression)
Measured: up to approximately 23 months
Disease control rate (rate of partial response plus complete response plus stable disease for at least 6 weeks)
Measured: up to approximately 23 months
Safety: Incidence of adverse events
Measured: up to approximately 23 months
Pharmacokinetics: serum concentration (Cmin/Cmax)
Measured: Pre- and post-dose on Day 1 of Cycles 1, 2 and 4 and at study termination
Serum concentrations of bevacizumab/paclitaxel/pemetrexed/platinum in combination with MetMAb
Measured: Pre- and post-dose on Day 1 of Cycles 1 and 4
Serum levels of anti-therapeutic antibodies (MetMAb ATAs)
Measured: Pre-dose Day 1 of Cycles 1, 2 and 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2011 (estimated)
- Study startApr 2012
- Primary completionNov 2015
- Study completionNov 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-Squamous Non-Small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by Genentech, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 259 participants (actual)
Sponsor and investigators
- Lead sponsor
- Genentech, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Genentech, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01496742
- Sponsor's protocol ID
- GO27821
- Other IDs
- 2011-003719-42
- Status last verified
- Sep 2016
- First submitted
- 19 Dec 2011
- Last updated
- 23 Sep 2016
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC
- ClinicalTrials.gov ID
- NCT01496742
- Acronym / sponsor ID
- GO27821
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 259 participants (actual)
- Lead sponsor
- Genentech, Inc.Industry (pharma, biotech, devices)
- Study start
- Apr 2012
- Primary completion
- Nov 2015 (actual)
- Study completion
- Nov 2015 (actual)
- First posted
- 21 Dec 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV non-squamous non-small cell lung cancer. In Cohort 1, patients will be randomized to receive 4 cycles of bevacizumab (Avastin) 15 mg/kg iv, paclitaxel 200 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMab 15 mg/kg iv or placebo on Day 1 of each 21-day cycle. In Cohort 2, patients will be randomized to receive pemetrexed 500 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMAb 15 mg/m2 iv or placebo on Day 1 of each 21-day cycle. Patients who have not progressed after 4 cycles will be offered maintenance therapy with their assigned treatment of bevacizumab plus either MetMAb or placebo (Cohort 1) or pemetrexed plus either MetMAb or placebo (Cohort 2). Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Bevacizumab+MetMAb | Experimental | Drug: RO5490258, Drug: bevacizumab [Avastin], Drug: cisplatin/carboplatin, Drug: paclitaxel |
| Bevacizumab+Placebo | Active comparator | Drug: Placebo, Drug: bevacizumab [Avastin], Drug: cisplatin/carboplatin, Drug: paclitaxel |
| Pemetrexed+MetMAb | Experimental | Drug: RO5490258, Drug: cisplatin/carboplatin, Drug: pemetrexed |
| Pemetrexed+Placebo | Active comparator | Drug: Placebo, Drug: cisplatin/carboplatin, Drug: pemetrexed |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adult patients, >/= 18 years of age
- Histologically or cytologically confirmed Stage IIIB or Stage IV non-squamous non-small cell lung cancer (NSCLC)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- For patients who received prior adjuvant chemotherapy or chemoradiotherapy: a treatment-free interval of at least 12 months since last chemotherapy or chemoradiotherapy cycle
- Adequate tissue for central immunohistochemical (IHC) assay of Met receptor, and epidermal growth factor receptor (EGFR) testing if EGFR status is unknown
Key exclusion criteria (11 listed)
- Prior systemic treatment for Stage IIIB or IV non-squamous NSCLC
- Evidence of mixed NSCLC with a predominance of the squamous cell type
- Prior exposure to experimental treatment targeting either the hepatocyte growth factor (HGF) or Met pathway
- Patients with tumors confirmed to have EGFR-activating mutations who are suitable for anti-EGFR therapy (e.g. gefitinib or erlotinib), as determined by the investigator, unless that treatment is unavailable or refused by the patient
- Known central nervous system (CNS) disease, other than stable, treated brain metastases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboMatching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle | Drug | Bevacizumab+Placebo, Pemetrexed+Placebo |
| RO5490258Also: MetMAb15 mg/kg iv, Day 1 of each 21-day cycle | Drug | Bevacizumab+MetMAb, Pemetrexed+MetMAb |
| bevacizumab [Avastin]15 mg/kg iv, Day 1 of each 21-day cycle | Drug | Bevacizumab+MetMAb, Bevacizumab+Placebo |
| cisplatin/carboplatinstandard dose iv, Day 1 of each 21-day cycle, 4 cycles | Drug | Bevacizumab+MetMAb, Bevacizumab+Placebo, Pemetrexed+MetMAb, Pemetrexed+Placebo |
| paclitaxel200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles | Drug | Bevacizumab+MetMAb, Bevacizumab+Placebo |
| pemetrexed500 mg/m2, Day 1 of each 21-day cycle | Drug | Pemetrexed+MetMAb, Pemetrexed+Placebo |
Primary outcome
Progression-free survival (tumor assessments according to RECIST criteria)
Time frame: up to approximately 23 months
Progression-free survival: Subgroup of patients with Met diagnostic positive tumors
Time frame: up to approximately 23 months
8 secondary outcomes
Overall survival
Time frame: up to approximately 23 months
Overall response rate (tumor assessments according to RECIST criteria)
Time frame: up to approximately 23 months
Duration of response (time from first documented objective response to disease progression)
Time frame: up to approximately 23 months
Disease control rate (rate of partial response plus complete response plus stable disease for at least 6 weeks)
Time frame: up to approximately 23 months
Safety: Incidence of adverse events
Time frame: up to approximately 23 months
Pharmacokinetics: serum concentration (Cmin/Cmax)
Time frame: Pre- and post-dose on Day 1 of Cycles 1, 2 and 4 and at study termination
Serum concentrations of bevacizumab/paclitaxel/pemetrexed/platinum in combination with MetMAb
Time frame: Pre- and post-dose on Day 1 of Cycles 1 and 4
Serum levels of anti-therapeutic antibodies (MetMAb ATAs)
Time frame: Pre-dose Day 1 of Cycles 1, 2 and 4
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2016.
Related trials for Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Not yet recruitingPhase 2
Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology
Active, not recruitingPhase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Non-small Cell Lung Cancer
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Genentech, Inc.
87 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing RO5490258, bevacizumab [Avastin] and cisplatin/carboplatin in people with Non-Squamous Non-Small Cell Lung Cancer, run by Genentech, Inc. at 87 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 87 sites in United States, Italy, Germany, Israel, Malaysia and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-free survival (tumor assessments according to RECIST criteria) (time frame: up to approximately 23 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2016.